2016-07-25 19:59:16 UTC

What Happens to Infants Whose Mothers Took Anti-TNF Agents During Pregnancy?

July 25, 2016

Gastro study says anti-TNF agents can be detected in infants born to mothers with IBD who took the drugs during pregnancy.

Anti-tumor necrosis factor (TNF) agents can be detected in infants born to mothers with inflammatory bowel diseases (IBD) who took the drugs during pregnancy, researchers report in the July issue of Gastroenterology. Infliximab is cleared more slowly than adalimumab from infants. However, measurable levels in infants do not seem to be of significant clinical consequence, researchers say.

Women of reproductive age with IBD face the challenge of being healthy enough to conceive and carry a successful pregnancy, while also having to protect the fetus from the potential adverse effects of drugs needed to maintain remission.

To read more about this study and its findings, head to the AGA Journals Blog for a comprehensive study overview.

More on Crohn's Disease

Crohn's & Colitis Congress™ (A Partnership of the Crohn's & Colitis Foundation and American Gastroenterological Association)

Jan. 18, 2018

Expand your knowledge, network with IBD leaders, spark innovative research and get inspired to improve patient care.

Putting Patients First: Digital Health Tools to Empower IBD Patients

Jan. 18, 2018

Discover how advances in digital health can help you monitor and support IBD patients remotely and dynamically, improve face-to-face care, and drive clinical decisions through shared decision-making.

Insurance Barriers Should Not Hinder Step Therapy Treatment for IBD

Dec. 13, 2017

AGA participated in a congressional briefing to highlight the need for physician use of step therapy treatment without barriers.